in this issue
Pharma/Fine Chemicals Roundup – June 21
June 21, 2011 | By DEEPTI RAMESH
Dr. Reddy’s API Site in Mexico Receives U.S. FDA Warning
Pharmaceutical company Dr. Reddy’s Laboratories (Hyderabad, India) says that Industrias Quimicas Falcon de Mexico, its wholly owned manufacturing facility at Cuernavaca, Mexico has received a warning letter from the U.S. Food and Drug Administration (FDA). The facility produces intermediates and active pharmaceutical ingredients (API).
Evonik Completes Glycine Expansion in China
Evonik Industries says it has increased production capacity for the pharmaceutical amino acid glycine by 50% at the company's facility at Nanning, China, citing growth in demand. The expansion was achieved through efficiency gains in the plant's production process.
Grindeks Opens API Plant in Latvia
Pharmaceutical company Grindeks (Riga, Latvia) says it has opened an active pharmaceutical ingredients (API) manufacturing unit at Riga. Construction of the plant began in 2009 following a cooperation agreement on regular ursodeoxycholic acid (UDCA) supply was signed with Marenis Pharma (Bingen am Rhein, Germany).
Tianyin Pharmaceutical Signs API Sales Deal with Bangladeshi Firm
Tianyin Pharmaceutical (Chengdu, China), a company that specializes in patented biopharmaceutical medicine, traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API) says it has signed a sales and marketing agreement with Relations International (Dhaka), a company that specializes in the sales of API for Tianyin’s azithromycin API product sales in Bangladesh.